BMI View: We expect heavy investment into Saudi Arabia's healthcare sector to continue, particularly as
the government sees the sector as key to the diversification of the economy. The medical tourism industry in
particular provides opportunities for both pharmaceutical and med ..."
BMI View: We hold a very positive outlook towards growth in the Saudi Arabian medicines market over the
next decade, with pharmaceutical demand underpinned by a number of factors. However, risks to our
outlook are to the downside, some of which include greater-than-ex ..."
BMI View: Despite some issues over its intellectual property (IP) regime, Saudi Arabia will continue to
present a considerable longer-term opportunity for pharmaceutical companies. The Kingdom - which is the
richest and largest of the Gulf states - has a large and gro ..."
BMI View: Saudi Arabia's large and wealthy population will continue to support demand for patented
medicines. While the country's intellectual property (IP) environment remains below par, multinationals
will remain interested in the market, as evidenced by Pfizer and Sanofi's i ..."
BMI View: Favourable demographic and epidemiological trends and the expansion of the country's healthcare services will continue to underpin the development of Saudi Arabia\s pharmaceutical market values. While challenges to market growth are posed by the factors such as strict p ..."
BMI View: King Abdullah's initiative to launch US$3.2bn worth of health projects in Saudi Arabia adds to the flurry of activity already occurring in the country's healthcare sector. It confirms our view that healthcare spending would be greatly boosted by government initiatives i ..."
Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forec ..."